Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study


Dwi Ris Andriyanto, - and Prihantono, - and Salman Ardi Syamsu, - and Muhammad Ihwan Kusuma, - and Joko Hendarto, - and Indra, - and Nilam Smaradania, - and Elridho Sampepajung, - and Asrul Mappiwali, - and Muhammad Faruk, - Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study. Annals of Medicine and Surgery 77 (2022) 103614.

[thumbnail of Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectom.pdf] Text
Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectom.pdf
Restricted to Repository staff only

Download (696kB)

Abstract (Abstrak)

Introduction: Premenopausal patients with hormone receptor-positive breast cancer require ablation therapy via a pharmacological or surgical approach. Data comparing outcomes between treatment with gonadotropin- releasing hormone (GnRH) analogs and treatment with bilateral salpingo-oophorectomy (BSO) in Indonesia remains limited. Therefore, this study aimed to compare incidence of local recurrence and metastasis, and overall survival (OS) in patients with luminal type breast cancer treated using the two approaches. Methods: This observational retrospective cohort study examined 100 premenopausal patients diagnosed with luminal type hormone receptor-positive breast cancer who registered at Dr. Wahidin Sudirohusodo Hospital and its networking hospitals in Makassar City from January to December 2017.
Result: Among the 100 study patients, 50 were given GnRH analogs and 50 underwent BSO. Incidence of local recurrence (P = 0.408) and metastasis (P = 0.419) did not significantly differ between the GnRH analog and BSO groups, although the incidence of local recurrence was higher in the GnRH analog group (68% vs. 58%) and incidence of metastasis was higher in the BSO group (24% vs 19%). The 5-year survival rate did not significantly differ between the GnRH analog and BSO groups.
Conclusion: Incidence of local recurrence and metastasis, and 5-year survival rate did not significantly differ between premenopausal breast cancer patients treated using a GnRH analog and those treated with BSO. Further large-scale studies to compare the efficacy and safety of both approaches are warranted.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Depositing User: - Andi Anna
Date Deposited: 23 Nov 2022 05:53
Last Modified: 23 Nov 2022 05:53
URI: http://repository.unhas.ac.id:443/id/eprint/23498

Actions (login required)

View Item
View Item